MTNB Stock Overview
Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates.
Matinas BioPharma Holdings Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$0.79|
|52 Week High||US$1.61|
|52 Week Low||US$0.49|
|1 Month Change||0.013%|
|3 Month Change||-1.25%|
|1 Year Change||1.74%|
|3 Year Change||-9.20%|
|5 Year Change||-50.63%|
|Change since IPO||-39.23%|
Recent News & Updates
|MTNB||US Biotechs||US Market|
Return vs Industry: MTNB exceeded the US Biotechs industry which returned -25.1% over the past year.
Return vs Market: MTNB exceeded the US Market which returned -21.2% over the past year.
|MTNB Average Weekly Movement||12.7%|
|Biotechs Industry Average Movement||13.2%|
|Market Average Movement||8.1%|
|10% most volatile stocks in US Market||16.8%|
|10% least volatile stocks in US Market||3.3%|
Stable Share Price: MTNB is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 13% a week.
Volatility Over Time: MTNB's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. It develops products using its lipid nanocrystal (LNC) platform technology. The company’s LNC delivery technology platform utilizes lipid nano-crystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides.
Matinas BioPharma Holdings Fundamentals Summary
|MTNB fundamental statistics|
Is MTNB overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|MTNB income statement (TTM)|
|Cost of Revenue||US$16.32m|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
|Earnings per share (EPS)||-0.11|
|Net Profit Margin||0.00%|
How did MTNB perform over the long term?See historical performance and comparison
Is MTNB undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 0/6
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for MTNB?
Other financial metrics that can be useful for relative valuation.
|What is MTNB's n/a Ratio?|
Price to Book Ratio vs Peers
How does MTNB's PB Ratio compare to its peers?
|MTNB PB Ratio vs Peers|
|Company||PB||Estimated Growth||Market Cap|
OMGA Omega Therapeutics
ORIC ORIC Pharmaceuticals
OLMA Olema Pharmaceuticals
MTNB Matinas BioPharma Holdings
Price-To-Book vs Peers: MTNB is expensive based on its Price-To-Book Ratio (3.6x) compared to the peer average (0.7x).
Price to Earnings Ratio vs Industry
How does MTNB's PE Ratio compare vs other companies in the US Biotechs Industry?
Price-To-Book vs Industry: MTNB is expensive based on its Price-To-Book Ratio (3.6x) compared to the US Biotechs industry average (1.5x)
Price to Book Ratio vs Fair Ratio
What is MTNB's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PB Ratio||3.6x|
|Fair PB Ratio||n/a|
Price-To-Book vs Fair Ratio: Insufficient data to calculate MTNB's Price-To-Book Fair Ratio for valuation analysis.
Share Price vs Fair Value
What is the Fair Price of MTNB when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate MTNB's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate MTNB's fair value for valuation analysis.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate MTNB's PEG Ratio to determine if it is good value.
Discover undervalued companies
How is Matinas BioPharma Holdings forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?
Future Growth Score2/6
Future Growth Score 2/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: MTNB is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: MTNB is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: MTNB is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: MTNB's revenue (85.2% per year) is forecast to grow faster than the US market (8.2% per year).
High Growth Revenue: MTNB's revenue (85.2% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if MTNB's Return on Equity is forecast to be high in 3 years time
Discover growth companies
How has Matinas BioPharma Holdings performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: MTNB is currently unprofitable.
Growing Profit Margin: MTNB is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: MTNB is unprofitable, but has reduced losses over the past 5 years at a rate of 3.4% per year.
Accelerating Growth: Unable to compare MTNB's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: MTNB is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (98.2%).
Return on Equity
High ROE: MTNB has a negative Return on Equity (-50.97%), as it is currently unprofitable.
Discover strong past performing companies
How is Matinas BioPharma Holdings's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: MTNB's short term assets ($45.1M) exceed its short term liabilities ($3.8M).
Long Term Liabilities: MTNB's short term assets ($45.1M) exceed its long term liabilities ($4.3M).
Debt to Equity History and Analysis
Debt Level: MTNB is debt free.
Reducing Debt: MTNB has no debt compared to 5 years ago when its debt to equity ratio was 0.2%.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: MTNB has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: MTNB has sufficient cash runway for 1.8 years if free cash flow continues to reduce at historical rates of 15.2% each year.
Discover healthy companies
What is Matinas BioPharma Holdings's current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate MTNB's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate MTNB's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if MTNB's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if MTNB's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as MTNB has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Jerry Jabbour (48 yo)
Mr. Jerome D. Jabbour, also known as Jerry, J.D., Co Founded Matinas BioPharma Holdings, Inc. and has been its Chief Executive Officer since March 16, 2018 and has been its President since March 7, 2016. M...
CEO Compensation Analysis
Compensation vs Market: Jerry's total compensation ($USD3.69M) is above average for companies of similar size in the US market ($USD1.83M).
Compensation vs Earnings: Jerry's compensation has increased whilst the company is unprofitable.
Experienced Management: MTNB's management team is considered experienced (3.6 years average tenure).
Experienced Board: MTNB's board of directors are considered experienced (4.5 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 6.2%.
Matinas BioPharma Holdings, Inc.'s employee growth, exchange listings and data sources
- Name: Matinas BioPharma Holdings, Inc.
- Ticker: MTNB
- Exchange: NYSEAM
- Founded: 2013
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$171.323m
- Shares outstanding: 216.86m
- Website: https://www.matinasbiopharma.com
Number of Employees
- Matinas BioPharma Holdings, Inc.
- 1545 Route 206 South
- Suite 302
- New Jersey
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/07/03 00:00|
|End of Day Share Price||2022/07/01 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.